Search
Research
Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemiaIt is now well accepted that germline or de novo genetic alterations predispose to cancer development, especially during childhood. Among them, constitutive trisomy 21, also known as Down syndrome (DS), has been shown to predispose to acute leukemia affecting both the myeloid (ML-DS) and lymphoid (DS-ALL) lineages. ML-DS is associated with a good prognosis compared to children without DS, due in part to a higher sensitivity to conventional chemotherapy.
News & Events
Friendly bacteria reduces flu symptoms and ear infections in miceResearch reveals that friendly bacteria may help reduce flu symptoms, offering new insights into potential treatments and enhancing our understanding of immune health.
News & Events
Hon. Julie Bishop to join Human Vaccines Project boardThe Kids Research Institute Australia Chair Hon. Julie Bishop will join the international Human Vaccines Project’s Board of Directors on its mission to address the next frontier of human health – decoding the human immune system to transform how we prevent, diagnose and treat disease.
Research
What does better look like in individuals with severe neurodevelopmental impairments? A qualitative descriptive study on SCN2A-related developmental and epileptic encephalopathyThere are limited psychometric data on outcome measures for children with Developmental Epileptic Encephalopathies (DEEs), beyond measuring seizures, and no data to describe meaningful change. This study aimed to explore parent perceptions of important differences in functional abilities that would guide their participation in clinical trials.
Research
Pacific Rheumatic Heart Disease (RHD) ProgramThe goal of the program is to establish the foundations of an effective, sustainable and equitable response to RHD in the Pacific.
Research
Head-to-head Pharmacokinetic Comparison of Bicillin ® L-A versus Lyophilised (Powdered) Benzathine Penicillin G administered by the Intramuscular and Subcutaneous RoutesFiji has one of the highest burdens of RHD is in the world and RHD is the second most common cause of death in young people in Fiji.
Research
Hospital admissions for skin and soft tissue infections in a population with endemic scabies: A prospective study in Fiji, 2018-2019Scabies is an important predisposing factor for impetigo but its role in more serious skin and soft tissue infections (SSTIs) is not well understood. Information is limited on incidence of SSTIs in the presence of endemic scabies. We conducted a prospective study of hospital admissions for SSTIs in the Northern Division of Fiji (population: 131,914). Prospective surveillance for admissions with impetigo, abscess, cellulitis, wound infection, pyomyositis, necrotizing fasciitis, infected scabies, and crusted scabies was conducted at the Division's referral hospital between 2018 to 2019. Information was collected on demographic characteristics, clinical features, microbiology, treatment and outcomes.
Research
The American Heart Association’s Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart AssociationJoseph Rosemary Jonathan Kado Wyber Carapetis AM PhD MBChB MPH FRACGP PhD AM MBBS FRACP FAFPHM PhD FAHMS Senior Research Fellow Senior Research
Research
The cost-of-illness due to rheumatic heart disease: national estimates for FijiWe estimate for the first time the total cost of RHD for Fiji (2008-2012) using a cost-of-illness approach and novel primary data on RHD disease burden and costs.
Research
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13.